✕

Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Summit Therapeutics (SMMT) Hits 52-Week Low After FDA Setback

Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the 10 Stocks Investors Are Dumping Right Now.

Summit Therapeutics fell for a 5th straight day on Monday to touch a new 52-week low after the Food and Drug Administration (FDA) thumbed down its Biologics License Application (BLA) for its lung cancer treatment candidate, Ivonescimab, amid a lack of substantial evidence in overall survival data.

In intraday trading, the stock nosedived to a record low of $11.54 before paring losses to end the day down 16.47 percent at $11.82 apiece.

Photo by Tima Miroshnichenko on Pexels

Summit Therapeutics Inc. said that the FDA rejected its BLA after determining that substantial evidence of effectiveness was not established amid the absence of a statistically significant improvement in enrolled patients’ overall survival.

Additionally, the FDA indicated that data on progression-free survival (PFS) without any improvement in overall survival do not support a positive benefit-risk profile.

The BLA was based on Summit Therapeutics Inc.’s data from its double-blind Phase 3 clinical trial, which aimed to study Ivonescimab in combination with chemotherapy, where PFS—its primary endpoint—was met.

The study found that Ivonescimab combined with chemotherapy was well-tolerated with no new safety signals and comparable rates of discontinuation and death.

However, 16 patients in the Ivonescimab group and 11 patients in the placebo group discontinued due to adverse effects.

Nine patients died, including four from the Ivonescimab plus chemotherapy arm group, and five in the chemotherapy alone.

“We are disappointed for patients and their families awaiting additional treatment options in this setting,” Chairman and CEO Robert Duggan said.

“With five positive Phase 3 studies between Summit and Akeso, nothing changes with respect to our ever-growing belief in the opportunity for Ivonescimab and our determination to advance Ivonescimab’s development. Our mission remains to improve outcomes for patients facing significant unmet needs, which is work worth doing, and we will continue through our expansive clinical development program,” he noted.

READ NEXT: Forget Nvidia: 10 Stocks Wall Street is Betting on Right Now and Buy Alert: 10 Stocks Analysts Upgraded on Friday

Follow Insider Monkey on Google News.